Medline (NASDAQ:MDLN) Shares Gap Down – Here’s What Happened

Medline (NASDAQ:MDLN) shares gapped down before the market opened on Wednesday . The stock had previously closed at $42.04, but opened at $37.30. Medline shares last traded at $36.86, with a volume of 2,710,444 shares changing hands.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter adjusted earnings of $0.50 per share, well above the $0.32 analyst consensus, on $7.69 billion in revenue. The company also raised its 2026 organic sales-growth outlook to 9%–10%, signaling continued demand for its medical-supply products. Medline Q2 Earnings Snapshot
• Positive Sentiment: BTIG maintained a Buy rating and $55 price target, citing robust growth and viewing current headwinds as temporary. William Blair also reaffirmed its Buy rating following the strong quarter and improved organic-growth guidance. BTIG Medline Rating
• Neutral Sentiment: Truist lowered its price target from $56 to $47, while Stifel reduced its target from $50 to $45. Both firms retained Buy ratings, implying analysts still see substantial long-term upside despite near-term concerns. Medline Analyst Target Changes
• Negative Sentiment: Medline reduced its 2026 adjusted EBITDA outlook to $3.3 billion–$3.4 billion, reflecting tariff costs, margin pressure and other headwinds. The lower profit forecast overshadowed the quarterly earnings beat and higher sales guidance. Medline Lowers EBITDA Outlook
• Negative Sentiment: Several law firms, including Kaplan Fox and Kessler Topaz Meltzer & Check, announced investigations into potential federal securities-law violations. The inquiries follow an FDA warning letter reportedly disclosing significant violations, creating additional legal and reputational risk for investors. Kessler Topaz Medline Investigation

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Tigress Financial boosted their price objective on Medline from $60.00 to $62.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Robert W. Baird set a $42.00 target price on Medline in a research report on Thursday. BMO Capital Markets restated an “outperform” rating and set a $47.00 target price on shares of Medline in a research note on Thursday. Weiss Ratings cut Medline from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, July 23rd. Finally, BTIG Research restated a “buy” rating and issued a $55.00 price objective on shares of Medline in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

Medline Price Performance

The company’s 50 day moving average is $38.24 and its 200 day moving average is $41.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.41 and a quick ratio of 2.51. The stock has a market cap of $45.15 billion and a price-to-earnings ratio of 107.34.

Medline (NASDAQ:MDLN) last posted its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.18. The firm had revenue of $7.68 billion during the quarter. Research analysts forecast that Medline will post 1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Jessi L. Corcoran purchased 5,000 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were bought at an average price of $34.15 per share, for a total transaction of $170,750.00. Following the acquisition, the insider directly owned 5,000 shares in the company, valued at $170,750. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Douglas P. Golwas sold 100,000 shares of Medline stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total value of $3,677,000.00. Following the completion of the transaction, the insider owned 23,899 shares in the company, valued at $878,766.23. The trade was a 80.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.81% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Medline

A number of institutional investors and hedge funds have recently bought and sold shares of MDLN. Carlyle Group Inc. bought a new stake in shares of Medline in the 4th quarter worth approximately $9,042,728,000. H&F Corporate Investors X Ltd. bought a new position in Medline in the 4th quarter valued at about $4,179,591,000. Vanguard Group Inc. bought a new position in shares of Medline in the fourth quarter valued at approximately $793,278,000. Morgan Stanley acquired a new position in Medline during the fourth quarter worth about $636,807,000. Finally, Capital Research Global Investors acquired a new position in Medline in the fourth quarter worth approximately $620,937,000.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.